Aster DM Healthcare growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+12.2%+11.9%−69.0%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+17.9%+32.3%−63.1%
+23.5%+44.1%−54.4%
−92.1%+2,456.2%−55.5%
−93.0%+4,053.1%−69.6%
+22.8%−63.3%+20.9%
+32.4%−27.4%+3.5%
+54.3%+169.3%−91.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ASTERDM₹679.20

Aster DM Healthcare Ltd.

· Pharma & Health
₹ CrorePeersAPOLLOHOSPMAXHEALTHKIMSCOHANCEWOCKPHARMASYNGENEGLANDLALPATHLABMcap ₹35,191 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—-69.0+11.9+12.2—
EBITDA Growth—-63.1+32.3+17.9—
EBIT Growth—-54.4+44.1+23.5—
Net Income Growth—-55.5+2,456.2-92.1—
EPS Growth—-69.6+4,053.1-93.0—
Total Assets Growth—+20.9-63.3+22.8—
Total Equity Growth—+3.5-27.4+32.4—
Cash from Operations Growth—-91.4+169.3+54.3—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.